- Record: found
- Abstract: not found
- Article: not found
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurélien Marabelle ,
Marwan Fakih ,
Juanita Lopez ,
Manisha Shah ,
Ronnie Shapira-Frommer ,
Kazuhiko Nakagawa ,
Hyun Cheol Chung ,
Hedy L Kindler ,
Jose A Lopez-Martin ,
Wilson H Miller ,
Antoine Italiano ,
Steven Kao ,
Sarina A Piha-Paul ,
Jean-Pierre Delord ,
Robert R McWilliams ,
David A Fabrizio ,
Deepti Aurora-Garg ,
Lei Xu ,
Fan Jin ,
Kevin Norwood ,
Yung-Jue Bang
September 2020
September 2020
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d38865627e355">Tumour mutational burden (TMB) has been retrospectively
correlated with response to
immune checkpoint blockade. We prospectively explored the association of high tissue
TMB (tTMB-high) with outcomes in ten tumour-type-specific cohorts from the phase 2
KEYNOTE-158 study, which assessed the anti-PD-1 monoclonal antibody pembrolizumab
in patients with selected, previously treated, advanced solid tumours.
</p>